12:00 AM
Aug 31, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Brentuximab vedotin: Completed Phase II enrollment

Seattle Genetics completed enrollment of 100 patients who previously received an autologous stem cell transplant in a single-arm, open-label, international, pivotal Phase II trial evaluating 1.8 mg/kg IV brentuximab vedotin given every 3 weeks. The...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >